FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553622874> ?p ?o ?g. }

• W2553622874 endingPage "2496" @default.
• W2553622874 startingPage "2496" @default.
• W2553622874 abstract "Abstract A COG Phase II pilot study was conducted to assess the efficacy of the novel re-induction regimen of ifosfamide/vinorelbine (IV) in pediatric patients with heavily pre-treated relapsed/refractory Hodgkin disease. The treatment regimen consisted of : Ifosfamide 3 gm/m2/d continuous 24-hr IV infusion on Days 1–4; MESNA 3 gm/m2/d continuous 24-hr IV infusion on Days 1–5; and vinorelbine 25 mg/m2/dose IV bolus on Days 1, 5. Filgrastim was administered on Day 6 of Cycle 1 at a dose of 5 μg/kg until ANC ≥ 1000/μl for 3 consecutive days or ≥ 10,000/μl for 1 day and on Day 6 of Cycle 2 at a dose of 10 μg/kg to continue daily until completion of peripheral stem cell mobilization. We report the results of the first phase of the study, that evaluated the re-induction regimen IV which was substantiated as an effective re-induction regimen based on acceptable toxicity profile, capacity to mobilize hematopoietic stem cells (CD34+), and response sufficient to allow subsequent stem-cell transplantation in a large fraction of patients. Twenty-nine patients were accrued on study; 12 male (41%), 17 female (59%); median age at time of enrollment was 16 (range 5–20 yrs). The protocol mandated two cycles of therapy, although some patients received an optional third cycle. This report is based on data from the first 2 cycles only. Twenty-five patients had complete toxicity data. The predominant toxicity was hematologic, specifically leukopenia/neutropenia. The frequencies of grade 3–4 hematologic toxicities included: anemia (62%), leukopenia (100%), neutropenia (95%), and thrombocytopenia (50%). Hypophosphatemia (3%), febrile neutropenia (34.9%) and infection with grade 3 or 4 neutropenia (21.6%), and neurotoxicity (3%), each occurred in a minority of patients. There were no toxic deaths. Harvest was attempted in 25 patients. At least 2.5 x 106 CD34+ cells/kg were collected in 19 (76%), and at least 5.0 x 106 were collected in 16 (64%). Complete response data were available for twenty-five patients. Seven patients attained a complete response (CR) and eleven a partial response (PR) (CR/PR rate 72%). IV was substantiated as an acceptable re-induction regimen for children with Hodgkin disease. It was effective, well tolerated, and allowed for collection of sufficient CD34+ cells to support peripheral stem cell transplantation. Based upon these findings, 35 additional patients will be accrued to more precisely establish the definitive response rate in pediatric patients. In addition, minimally pretreated patients will now be included, allowing assessment of response, toxicity and hematopoietic stem cells (CD34+) mobilization in minimally pre-treated patients as well as in the heavily pre-treated population." @default.
• W2553622874 created "2016-11-30" @default.
• W2553622874 creator A5003639088 @default.
• W2553622874 creator A5025395169 @default.
• W2553622874 creator A5037614274 @default.
• W2553622874 creator A5040001760 @default.
• W2553622874 creator A5047701227 @default.
• W2553622874 creator A5065627357 @default.
• W2553622874 creator A5086715435 @default.
• W2553622874 date "2004-11-16" @default.
• W2553622874 modified "2023-10-14" @default.
• W2553622874 title "AHOD00P1, a Pilot Study of Re-Induction Chemotherapy with Ifosfamide, and Vinorelbine (IV) in Children with Refractory/Relapsed Hodgkin Disease." @default.
• W2553622874 doi "https://doi.org/10.1182/blood.v104.11.2496.2496" @default.
• W2553622874 hasPublicationYear "2004" @default.
• W2553622874 type Work @default.
• W2553622874 sameAs 2553622874 @default.
• W2553622874 citedByCount "0" @default.
• W2553622874 crossrefType "journal-article" @default.
• W2553622874 hasAuthorship W2553622874A5003639088 @default.
• W2553622874 hasAuthorship W2553622874A5025395169 @default.
• W2553622874 hasAuthorship W2553622874A5037614274 @default.
• W2553622874 hasAuthorship W2553622874A5040001760 @default.
• W2553622874 hasAuthorship W2553622874A5047701227 @default.
• W2553622874 hasAuthorship W2553622874A5065627357 @default.
• W2553622874 hasAuthorship W2553622874A5086715435 @default.
• W2553622874 hasConcept C126322002 @default.
• W2553622874 hasConcept C141071460 @default.
• W2553622874 hasConcept C2776611710 @default.
• W2553622874 hasConcept C2776694085 @default.
• W2553622874 hasConcept C2777063308 @default.
• W2553622874 hasConcept C2777506904 @default.
• W2553622874 hasConcept C2778119113 @default.
• W2553622874 hasConcept C2778239845 @default.
• W2553622874 hasConcept C2778336483 @default.
• W2553622874 hasConcept C2778850193 @default.
• W2553622874 hasConcept C2780350996 @default.
• W2553622874 hasConcept C2780376820 @default.
• W2553622874 hasConcept C2781413609 @default.
• W2553622874 hasConcept C2911091166 @default.
• W2553622874 hasConcept C31760486 @default.
• W2553622874 hasConcept C71924100 @default.
• W2553622874 hasConcept C90924648 @default.
• W2553622874 hasConceptScore W2553622874C126322002 @default.
• W2553622874 hasConceptScore W2553622874C141071460 @default.
• W2553622874 hasConceptScore W2553622874C2776611710 @default.
• W2553622874 hasConceptScore W2553622874C2776694085 @default.
• W2553622874 hasConceptScore W2553622874C2777063308 @default.
• W2553622874 hasConceptScore W2553622874C2777506904 @default.
• W2553622874 hasConceptScore W2553622874C2778119113 @default.
• W2553622874 hasConceptScore W2553622874C2778239845 @default.
• W2553622874 hasConceptScore W2553622874C2778336483 @default.
• W2553622874 hasConceptScore W2553622874C2778850193 @default.
• W2553622874 hasConceptScore W2553622874C2780350996 @default.
• W2553622874 hasConceptScore W2553622874C2780376820 @default.
• W2553622874 hasConceptScore W2553622874C2781413609 @default.
• W2553622874 hasConceptScore W2553622874C2911091166 @default.
• W2553622874 hasConceptScore W2553622874C31760486 @default.
• W2553622874 hasConceptScore W2553622874C71924100 @default.
• W2553622874 hasConceptScore W2553622874C90924648 @default.
• W2553622874 hasIssue "11" @default.
• W2553622874 hasLocation W25536228741 @default.
• W2553622874 hasOpenAccess W2553622874 @default.
• W2553622874 hasPrimaryLocation W25536228741 @default.
• W2553622874 hasRelatedWork W1964431856 @default.
• W2553622874 hasRelatedWork W1969867024 @default.
• W2553622874 hasRelatedWork W1975832547 @default.
• W2553622874 hasRelatedWork W2022973635 @default.
• W2553622874 hasRelatedWork W2101093575 @default.
• W2553622874 hasRelatedWork W2145951960 @default.
• W2553622874 hasRelatedWork W2163749153 @default.
• W2553622874 hasRelatedWork W2319511185 @default.
• W2553622874 hasRelatedWork W2428528889 @default.
• W2553622874 hasRelatedWork W49781724 @default.
• W2553622874 hasVolume "104" @default.
• W2553622874 isParatext "false" @default.
• W2553622874 isRetracted "false" @default.
• W2553622874 magId "2553622874" @default.
• W2553622874 workType "article" @default.